Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rolland Gyulai

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Cancers|December 11, 2025
Ten Years of Euromelanoma in Hungary: Nationwide Trends and Risk Factors for Skin Cancer in Central-Eastern EuropeBenjamin Tamás Papp, Krisztina Toplenszky, Henriette Ócsai, et al.
Scientific Reports|May 9, 2025
Quality of life changes after electrochemotherapy: a prospective single-center analysisPetra Rózsa, Ferenc Rárosi, Henriette Ócsai, et al.
Journal of Clinical Medicine|April 30, 2021
Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous PemphigoidÁgnes Kinyó, Anita Hanyecz, Zsuzsanna Lengyel, et al.
Magyar Onkologia|March 12, 2026
[Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for the development of a national guideline.]László Mangel, Tímea Balatoni, Krisztina Bogos, et al.
British Journal of Pharmacology|May 1, 2026
Contact sensitisers activate keratinocytes and induce cytotoxicity via Transient Receptor Potential Ankyrin 1 in allergic contact dermatitisAreej Jaber, Szabina Horváth, Balázs Zoltán Zsidó, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2004
Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferationHideaki Sugiyama, Rolland Gyulai, Eiko Toichi, et al.
International Journal of Molecular Sciences|March 27, 2025
Activation of the Mammalian Target of Rapamycin Pathway in Endothelial Cells in Antiphospholipid Antibody-Positive Patients with Leg UlcersAndrás L Kovács, Csaba Gyömörei, Szabina Horváth, et al.
Acta Dermato-Venereologica|September 23, 2020
Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A Network Meta-analysisJúlia Szebényi, Noémi Gede, Péter Hegyi, et al.
Pharmaceuticals (Basel, Switzerland)|January 21, 2022
Presence of TRPA1 Modifies CD4+/CD8+ T Lymphocyte Ratio and ActivationKatalin Szabó, Ágnes Kemény, Noémi Balázs, et al.
International Journal of Molecular Sciences|October 26, 2024
The Expression of Cytokines and Chemokines Potentially Distinguishes Mild and Severe Psoriatic Non-Lesional and Resolved Skin from Healthy Skin and Indicates Different Stages of InflammationRenáta Bozó, Lili Borbála Flink, Barbara Ambrus, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Cancers|December 11, 2025
Ten Years of Euromelanoma in Hungary: Nationwide Trends and Risk Factors for Skin Cancer in Central-Eastern EuropeBenjamin Tamás Papp, Krisztina Toplenszky, Henriette Ócsai, et al.
Scientific Reports|May 9, 2025
Quality of life changes after electrochemotherapy: a prospective single-center analysisPetra Rózsa, Ferenc Rárosi, Henriette Ócsai, et al.
Journal of Clinical Medicine|April 30, 2021
Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous PemphigoidÁgnes Kinyó, Anita Hanyecz, Zsuzsanna Lengyel, et al.
Magyar Onkologia|March 12, 2026
[Could the administration of immune checkpoint inhibitors be discontinued after 2 years of application? Pros and cons for the development of a national guideline.]László Mangel, Tímea Balatoni, Krisztina Bogos, et al.
British Journal of Pharmacology|May 1, 2026
Contact sensitisers activate keratinocytes and induce cytotoxicity via Transient Receptor Potential Ankyrin 1 in allergic contact dermatitisAreej Jaber, Szabina Horváth, Balázs Zoltán Zsidó, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 22, 2004
Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferationHideaki Sugiyama, Rolland Gyulai, Eiko Toichi, et al.
International Journal of Molecular Sciences|March 27, 2025
Activation of the Mammalian Target of Rapamycin Pathway in Endothelial Cells in Antiphospholipid Antibody-Positive Patients with Leg UlcersAndrás L Kovács, Csaba Gyömörei, Szabina Horváth, et al.
Acta Dermato-Venereologica|September 23, 2020
Efficacy of Biologics Targeting Tumour Necrosis Factor-alpha, Interleukin-17 -12/23, -23 and Small Molecules Targeting JAK and PDE4 in the Treatment of Nail Psoriasis: A Network Meta-analysisJúlia Szebényi, Noémi Gede, Péter Hegyi, et al.
Pharmaceuticals (Basel, Switzerland)|January 21, 2022
Presence of TRPA1 Modifies CD4+/CD8+ T Lymphocyte Ratio and ActivationKatalin Szabó, Ágnes Kemény, Noémi Balázs, et al.
International Journal of Molecular Sciences|October 26, 2024
The Expression of Cytokines and Chemokines Potentially Distinguishes Mild and Severe Psoriatic Non-Lesional and Resolved Skin from Healthy Skin and Indicates Different Stages of InflammationRenáta Bozó, Lili Borbála Flink, Barbara Ambrus, et al.
Pageof 6